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Abstract: Following peripheral nerve injury, dysregulations of certain non-coding microRNAs
(miRNAs) occur in Schwann cells. Whether these alterations are the result of local inflammation
and/or correlate with perturbations in the expression profile of the protective vasoactive intestinal
peptide (VIP)/pituitary adenylate cyclase-activating polypeptide (PACAP) system is currently
unknown. To address these issues, we aimed at profiling the expression of selected miRNAs in the rat
RT4 Schwann cell line. Cells exposed to lipopolysaccharide (LPS), to mimic the local inflammatory
milieu, were appraised by real-time qPCR, Western blot and ELISAs. We found that upon LPS
treatment, levels of pro-inflammatory cytokines (IL-1β, -6, -18, -17A, MCP-1 and TNFα) increased
in a time-dependent manner. Unexpectedly, the expression levels of VIP and PACAP were also
increased. Conversely, levels of VPAC1 and VPAC2 receptors were reduced. Downregulated miRNAs
included miR-181b, -145, -27a, -340 and -132 whereas upregulated ones were miR-21, -206, -146a,
-34a, -155, -204 and -29a, respectively. Regression analyses revealed that a subset of the identified
miRNAs inversely correlated with the expression of VPAC1 and VPAC2 receptors. In conclusion,
these findings identified a novel subset of miRNAs that are dysregulated by immune challenge whose
activities might elicit a regulatory function on the VIP/PACAP system.
Keywords: miRNA; PACAP; VIP; Schwann cells; peripheral nerve; lipopolysaccharide; inflammation;
neuropeptides
1. Introduction
Axons of the peripheral nervous system (PNS), as opposed to those of the central nervous system
(CNS), exhibit high capacity of regeneration after lesion. This is due to intrinsic properties of PNS
neurons, but also largely depends on the activity of extrinsic factors that allow and promote axonal
regeneration in the PNS [1]. Schwann cells (SCs), the PNS myelinating glia, hold major functions
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in creating an environment that is favorable for axonal regrowth, stimulating axon outgrowth after
lesion, and rebuilding myelin sheaths of regenerated axons [2]. In intact nerves, SCs are present in two
differentiated states, either myelinating axons (myelinating SCs) or ensheathing groups of small-calibre
axons in Remak bundles (non-myelinating SCs). In contrast, following injury, differentiated SCs
reprogram to progenitor-like cells. Dedifferentiated SCs shut down the myelination program and
acquire new phenotypes coordinately to support nerve repair. These phenotypes include (1) secretion of
neurotrophic factors to promote axonal survival; (2) clearance of myelin debris to generate a favorable
environment for axonal regrowth; (3) initiation of inflammatory responses to promote wound healing;
and (4) proliferation to replace dead cells [1,3].
In previous studies, we have demonstrated that two naturally occurring neuroprotective peptides,
pituitary adenylate cyclase-activating polypeptide (PACAP) and the structurally related vasoactive
intestinal peptide (VIP), are actively involved in regulating some of the above indicated phenotypic
changes in SC lines [4–6]. The biological functions of these peptides are mediated by two receptor
subtypes, PAC1 and VPAC receptors. PAC1 has very high affinity for PACAP and lower for VIP,
whereas VPAC receptor subtypes (comprising VPAC1 and VPAC2 receptors) display equal and high
affinity for both PACAP and VIP [7–9]. Due to the intrinsic complexity and number of functions
elicited by these peptides in SCs, we reasoned that PACAP and VIP biological activities could be
the result of a crosstalk between the endogenous VIP/PACAPergic system and a system capable
of epigenetically controlling the expression of multiple genes. Interestingly, recent evidence has
proposed that following peripheral nerve injury, the progressive transition of SCs from a myelinating
phenotype towards the different progenitor-like phenotypes is largely dependent on the wound
microenvironment, which features the local presence of several growth factors and a robust acute
inflammatory activity [10]. According to these authors, some elements of the wound microenvironment
may trigger post-transcriptional changes to initiate in SCs the reprogramming that ultimately supports
the peripheral nerve regeneration process [10]. In this context, we questioned whether a class of small
non-coding molecules, namely microRNAs (miRNAs), could play a role in SCs reprogramming in
light of the fact that miRNAs are potent post-transcriptional regulators able to regulate the expression
of up to 1000 genes [11].
MicroRNAs (miRNAs) are small (approx. 22 nucleotides) non-coding RNAs capable of
post-transcriptionally silencing mRNAs that contain sequences complementary to the miRNAs’ 7- to
8-bp “seed” sequence [12,13]. MiRNAs have been implicated as regulators of various cellular and
physiological processes such as differentiation, proliferation, and cancer (reviewed by [14]). In the
framework of nerve injury, critical for post-injury phenotypic transitions of SCs from one stage to the
next is the repression of genes involved in the antecedent stage, as well as the activation of new genes
that will define the succeeding stage [15,16].
In the present study we set out to shed more light into these processes by investigating
whether an immune challenge with lipopolysaccharide (LPS) (to mimic inflammation), could trigger
dysregulations in the expression profiles of select miRNAs with well-established biological activities
in SCs, as well as in the VIP/PACAP neuroprotective system using an in vitro model of cultured rat
RT4 SCs. In addition, we performed regression analyses to identify potential correlations between
miRNAs and VIP/PACAP system gene expression profiles. Our hypothesis is that following an
inflammatory insult, the pattern of selected miRNAs known to be involved in biological functions
pertinent to the repair phenotype will be dysregulated in cultured SC lines, whose target genes
potentially include members of the endogenous VIP/PACAP system.
2. Results
2.1. Effects of LPS Treatment on RT4 SCs Viability
In order to identify the maximum LPS concentration needed to achieve inflammation in SCs
without causing any significant cell death we conducted both dose-response and time-course analyses
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of cell viability and Hoechst 33258 staining in RT4 SCs treated with LPS. Initially, cells were exposed to
increasing concentrations of LPS (0, 0.1, 1, 10 and 100 µg/mL) at a fixed time point of 24 h. As shown
in Figure 1 (panel A), LPS concentrations up to 1 µg/mL were devoid of statistically significant
effects on cell viability after 24 h (F4,35 = 8.608, p >0.05, ANOVA followed by Dunnett’s post-hoc test).
When concentrations were increased by an order of magnitude or two (10 or 100 µg/mL) we observed
significant reductions of viability (* p = 0.0172 or *** p = 0.0003, respectively). To confirm further
these findings through morphological observations, we performed Hoechst staining using the same
experimental conditions as indicated above. As depicted in Figure 1 (panel B), both 0.1 and 1 µg/mL
LPS caused only minor signs of chromatin condensation and no evidence of DNA fragmentation or
cell shrinkage, whereas overt signatures of cell death, including cell clustering, were observed in SCs
at the highest concentrations tested. Finally, to establish whether the 1 µg/mL LPS concentration was
suitable for testing over our planned experimental time window, we run a time-course analysis of
cell viability at different time intervals (0, 12, 24, 36 and 48 h) (Figure 1, panel C). One-way ANOVA
and post-hoc analyses confirmed that no significant reductions of cell viability could be found at any
of the time points tested (F4,35 = 1.962, p > 0.05 at every time points), although proliferation was in
part hinder, but still qualifying the 1 µg/mL LPS as the most suitable concentration for the purpose of
this study.
Figure 1. Effects of LPS treatment on RT4 SCs viability. Analysis of cell viability (MTT assay) (A) in
RT4 SCs grown under normal conditions (Ctrl), or supplemented with increasing concentrations of
LPS for 24 h. Values reported represent the mean optical densities (OD) ± S.E.M. from four separate
assessments, each run in duplicate using separate cell batches (n = 8). * p < 0.05 or *** p < 0.001 vs.
Ctrl, as calculated using One-Way analysis of variance (ANOVA) followed by Dunnett’s post-hoc
test; (B) Hoechst 33258 staining in RT4 SCs treated as in A. Cells were fixed with a solution of
methanol/acetic acid (3:1, v/v) for 30 min, washed three times in PBS and incubated for 15 min at
37 ◦C with 0.4 µg/mL Hoechst 33,258 dye and analyzed for morphological characteristics of apoptosis
under a fluorescence microscope (Axiovert, Zeiss). Original magnification = 63.5×. Scale bar = 20 µm;
(C) Time-course analyses of cell viability in RT4 SCs exposed to a fixed concentration of LPS (1µg/mL)
at different time points (0, 12, 24, 36 and 48 h). Statistical analyses and number of biological replicates
as in A.
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2.2. Effects of LPS Treatment on RT4 SCs Inflammatory Profile
Similarly to microglia, SCs express several pattern recognition receptors that allows them to
recognize danger signals and respond by secreting cytokines and chemokines, to further attract
immune cells to the site of injury [17]. Here, to test the validity of our cellular model in mimicking
in vivo SCs responses to inflammatory/danger signals, we opted to test the effects of LPS treatment on
the secretion of pro-inflammatory cytokine in our rat RT4 SCs. Customized multiplex cytokine assays
were run in RT4 SCs exposed to 1 µg/mL LPS over a range of time points (0, 2, 4, 12, 24, 36 and 48 h,
respectively) to assess the levels of 6 different pro-inflammatory cytokines/chemokines: interleukin
(IL)-1β, IL-6, IL-18, IL-17A, monocyte chemotactic protein-1 (MCP-1) and tumor necrosis factor-α
(TNF-α). Results demonstrated that, albeit at different degrees, LPS treatment remarkably increased
the levels of secreted cytokines/chemokines in the culture media (Figure 2, panels A–F). Specifically,
a progressive elevation of IL-1β levels was seen over time, with values becoming statistically significant
vs. controls after 12 h LPS exposure (F6, 14 = 8.93, ** p = 0.002; ANOVA followed by Dunnett’s
post-hoc test) or above (*** p < 0.0001). IL-6 required prolonged exposure to LPS (≥24 h) to increase
at significant levels (F6,14 = 11.68, * p = 0.0147 at 24 h, * p = 0.028 at 36 h and *** p = 0.0003 at 48 h,
respectively). IL-18 secretion spiked early following LPS treatment, with significant increases already
after 2 h (F6,14 = 10.71, * p = 0.0137). Cytokine secretion peaked at 4 h (*** p = 0.0001), plateaued until
24 h (*** p = 0.0001) and then slightly reduced at 36 h (** p = 0.0023) and 48 h (** p = 0.0024). The levels
of IL-17A steadily increased and values were statistically significant as early as after 4 h, peaked at 24 h
and then moderately diminished by 48 h (F6,14 = 28.01, *** p = 0.0001). The pattern of MCP-1 secretion
(aka chemokine (C-C motif) ligand 2, CCL-2) was somewhat different. Levels in the media were not
much increased up to 4 h post-LPS exposure (F6,14 = 13.44, p = 0.6333 at 2 h, p = 0.3243 at 4 h), but then
rapidly augmented at 12 h (** p = 0.0032) to reach plateau after 24 h and after (*** p = 0.0002). Finally,
TNF-α increased at significant levels after 2 h (F6,14 = 9.855, * p = 0.0234) and maintained steady levels
until 4 h (* p = 0.0287), to rise again at 12 h (*** p = 0.0009) and 24 h (*** p = 0.0001) and then slightly
attenuate at the following time points (*** p = 0.001 both after 36 and 48 h LPS exposure).
Figure 2. Cont.
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Figure 2. (A–F) Levels of secreted pro-inflammatory cytokine/chemokines in RT4 SCs treated with
LPS at different time points (0, 2, 4, 12, 24, 36 and 48 h) were determined using commercially available
Bio-Plex Pro Rat Cytokine I multiplex assay kits (for details refer to Materials and Methods section).
Data shown is the result of three independent determinations (n = 3), each run in duplicate. * p < 0.05,
** p < 0.01 or *** p < 0.001 vs. time 0, as determined by ANOVA followed by Dunnett’s post-hoc test.
2.3. VIP/PACAP System Gene Expression Profile Following LPS Treatment
The VIP/PACAP system is involved in regulating a myriad of biological functions in SCs,
including inhibition of apoptosis [6], synthesis of myelin components [4] and production of proteolytic
enzymes to provide axonal guidance and digestion of cell debris [5]. Since some of these functions are
strongly enhanced following the transition of SCs to a de-differentiated “repair phenotype” [17],
we sought to determine the gene expression levels of each VIP/PACAP family component in
RT4 SCs following LPS exposure. LPS treatment rapidly induced VIP (Vip) gene expression in SCs,
by significantly increasing mRNA levels both at 2 h (F6,35 = 20.19, *** p = 0.0004) and 4 h (*** p < 0.0001)
to plateau at about 2.3-fold increase thereafter (*** p < 0.0001) (Figure 3, panel A). Despite significant,
PACAP (Adcyap1) gene levels exhibited a more blunted increase in response to LPS, with an average
overall increase of ~1.4–1.5-fold when compared with controls over the entire time-window tested
(F6,35 = 4.507, * p = 0.0163 at 2 h, * p = 0.0189 at 4 h, ** p = 0.0021 at 12 h, ** p = 0.0014 at 24 h,
*** p = 0.0007 at 36 h and ** p = 0.0015 at 48 h) (Figure 3, panel B). Expression of the PACAP-preferring
PAC1 receptor (Adcyap1r1) gene was unaffected by treatment at any of the time points assessed (F6,35 =
0.6618, p = 0.6618) (Figure 3, panel C). Conversely, both VPAC1 (Vipr1) and VPAC2 (Vipr2) mRNAs
were significantly downregulated by the immune challenge. More specifically, Vipr1 transcripts were
significantly lower than controls after 12 h (0.68-fold, F6,35 = 4.801, * p = 0.0414) and 24 h (0.61-fold,
** p = 0.0081) to slowly recover to control levels after 36 and 48 h (0.82 and 1.01-fold, p = 0.4453 and
0.9997, respectively) (Figure 3, panel D). Vipr2 reduction happened earlier when compared with Vipr1,
with significantly reduced gene expression as early as after 2 h LPS exposure (0.67-fold, F6,35 = 3.34,
* p = 0.0178) and lasting until 36 h (0.62-fold, ** p = 0.0054 at 4 h, 0.61-fold, ** p = 0.0046 at 12 h, 0.71-fold,
* p = 0.0364 at 24 h and 0.66-fold, * p = 0.0127 at 36 h, respectively) to finally return almost to baseline
levels by 48 h (0.81-fold, p = 0.2493) (Figure 3, panel E).
Figure 3. Cont.
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Figure 3. Time-course gene expression profiling of (A) Vip; (B) Adcyap1; (C) Adcyap1r1; (D) Vipr1
and (E) Vipr2 mRNAs in RT4 SCs treated with LPS at the indicated concentration. Relative transcript
levels were measured by quantitative real-time PCR analyses. Amplifications were performed using
selected primers optimized for qPCR analyses (<150 bp length) recognizing fragments within the
CDS of the gene of interest (for details refer to Table 1 below). Results are presented as mean fold
changes of time 0 (control) ± SEM. Fold changes of each gene were obtained after normalization to the
endogenous ribosomal protein S18 (reference gene) and then calculated using the comparative ∆∆Ct
method. Baseline expression levels of control were set to 1. Bar graphs depicted show the mean results
obtained from two independent determinations using two separate batches of cells each time (n = 4).
* p < 0.05, ** p < 0.01 or * p < 0.001, as determined using ANOVA and Dunnett’s post-hoc comparisons.
Table 1. Primer sets used to determine mRNAs changes within the VIP/PACAP system in the
RT4 Schwann cell line.





Rattus norvegicus adenylate cyclase activating
polypeptide 1 (Adcyap1) (NM_016989.2)
5′-GAGGCTTACGATCAGGACGG-3′ 414 59.97
1213′-TCCTGTCGGCTGGGTAGTAA-5′ 534 59.96








Rattus norvegicus vasoactive intestinal peptide
receptor 1 (Vipr1) (NM_012685.2)
5′-AAGCTGCACTGTACCCGAAA-3′ 597 59.89
1033′-CGCTGTTGAAGAGGGCCATA-5′ 699 60.11
Rattus norvegicus vasoactive intestinal peptide
receptor 2 (Vipr2) (NM_017238.1)
5′-TGACCTGCTACTGCTGGTTG-3′ 135 59.96
1383′-CGCTGCAAGCTCTGTGATTC-5′ 272 59.9




Sense and antisense primers were selected from the 5′ and 3′ region of each gene coding region. The expected length
of each amplicon is depicted in the right column.
2.4. VIP/PACAP System Protein Expression Profile Following LPS Treatment
To investigate whether the expression of each of the components of the VIP/PACAP system
was perturbed in response to LPS exposure, Western blot analyses were carried out in cells after 24 h
treatment. Results are depicted in Figure 4 below. As demonstrated by semi-quantitative analyses
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of blots intensities, treatment with LPS caused a significant increase in the expression of both VIP
(t6 = 6.77, *** p = 0.0005, as determined using the unpaired Student t-test) and to lesser extent, of PACAP
protein levels compared with untreated controls in SCs (t6 = 5.207, *** p = 0.002) (Figure 4, panels A–C).
Similarly to mRNA data, PAC1 expression was unaffected by treatment (t6 = 1.627, p = 0.1548) whilst
VPAC1 and VPAC2 were significantly reduced (VPAC1→ t6 = 8.794, *** p = 0.0001; VPAC2→t6 = 2.936,
* p = 0.0261, respectively) (Figure 4, panels A, D–F).
Figure 4. (A) Representative Western blots showing the effects of 24 h exposure to 1 µg/mL LPS in
RT4 SCs. Semi-quantitative analyses of bands’ intensities show significant increases both in (B) VIP and
(C) PACAP protein expression levels, but not in (D) PAC1 receptor, which was unaffected by treatment.
Conversely, both (E) VPAC1 and (F) VPAC2 receptor levels were diminished. Data are the mean± SEM
of two experiments, each using 2 separate batches of cells per group (n = 4). * p < 0.05 or *** p < 0.0001
vs. Ctrl; Unpaired Student t-test.
2.5. Dynamics of miRNAs Expression in RT4 SCs Exposed to LPS Treatment
With the idea of investigating the expression profile of select miRNAs previously shown to
regulate certain functions of SCs pertinent to the post-injury transition to the “repair phenotype” in
our cell model, we first conducted a thorough literature research in the attempt to identify the most
relevant candidates. As shown in Table 2, we identified 18 putative miRNA candidates. Downstream
time-course analyses of gene expression by RT-qPCR demonstrated that only 12 of the identified
miRNAs were significantly dysregulated by LPS treatment in our cell system (Figures 5 and 6 below),
whereas six miRNAs were not significantly affected.
The heatmap depicted in Figure 5 (panel A) illustrates the pattern of expression of the dysregulated
miRNAs, characterized by the presence of 5 significantly downregulated (i.e., rno-miR-181b, -145, -27a,
-340 and -132) and 7 significantly upregulated miRNAs (i.e., rno-miR-21, -206, -146a, -34a, -155, -204
and -29a).
Table 2. Selection of miRNAs based on their involvement in regulating biological processes relevant to
the Schwann cell “repair phenotype”.
miRNA Putative Role in SCs Identified Targets Reference(s)
miR-221 Cell migration, myelin genes LAAS2 [18,19]
miR-222 Cell migration, myelin genes LAAS2 [18,19]
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Table 2. Cont.
miRNA Putative Role in SCs Identified Targets Reference(s)
miR-29a Myelin genes, motility PMP-22, CDK6 [20,21]
miR-21 Cell differentiation SOX-2 [22]
miR-9 Cell migration Cthrc1 [23]
miR-27a Cell proliferation FOXO1 [24]
miR-34a De-differentiation genes, apoptosis Notch1, Ccnd1, Bcl2, XLAP [25,26]
miR-132 Cell migration PRKAG3 [27]
miR-145 De-differentiation genes Egr2, c-Jun, MPZ [25,28]
miR-210 Cell proliferation & migration GAP-43, MAG, MBP [29]
miR-146a Schwann cell development SOX-10 [30]
miR-155 Inflammatory response Toll-like receptors [31]
miR-181b Inflammation (in astrocytes) MeCP2, XLAP [32]
miR-182 Cell proliferation and migration FGF9, NTM [33]
miR-204 Apoptotic process Neuritin [34]
miR-206 Oncogenic transformation NF2, ERBB2, NRG1 [35]
miR-137 Tumor suppressor function NF1, MK2 [36,37]
miR-340 Production of proteolytic enzymes tPA [38]
MiRNAs whose expression levels were significantly dysregulated following LPS treatment are indicated in bold.
Unaffected miRNAs are printed using regular font.
2.5.1. Downregulated miRNAs
Repeated measures ANOVA followed by Fisher’s LSD test demonstrated that rno-miR-181b was
significantly diminished after 2 h LPS (0.75-fold vs. Ctrl, F6,27 = 73.95, ** p = 0.0052) and further
reduced till the 48 h time point (0.58-fold at 4 h, ** p = 0.0012; 0.67-fold at 12 h, ** p = 0.0069;
0.42-fold at 24 h, *** p = 0.0005, 0.44-fold at 36 h, *** p = 0.0008 and 0.36-fold at 48 h, *** p = 0.0004,
respectively). Rno-miR-145 levels were robustly reduced after 2 and 4 h (F6,27 = 96.44, 0.41-fold both at
2 h, *** p = 0.0004 and 4 h, *** p < 0.0001), slightly increased at 12 and 24 h (0.7-fold, ** p = 0.0021 and
0.68-fold, ** p = 0.002) to drop down again at the later times tested (0.33-fold at 36 h, *** p < 0.0001 and
0.54-fold at 48 h, *** p = 0.0003). The expression of rno-miR-27a reduced to less than 0.5-fold of control
after 2, 4 and 12 h treatment (F6,27 = 140.8, *** p = 0.0006 at 2 h and *** p < 0.0001 at 4 h and 12 h,
respectively). After 24 h, the decrease was much less evident with respect to controls, though still
significant (0.89-fold, * p = 0.0194), but decreased further at 36 h (0.66-fold, *** p = 0.0009) and 48 h
(0.77-fold, *** p < 0.0001). Rno-miR-340 pattern of expression was characterized by a slow and steady
decrease, which became statistically significant only after 12 h (0.56-fold, F6,27 = 17.83, ** p = 0.0071),
reached the minimum at 24 h (0.32-fold, *** p = 0.0009) to slightly augment thereafter (0.6-fold at 36 h,
** p = 0.0039 and 0.74-fold at 48 h, ** p = 0.0054). Regarding rno-miR-132, the time-course of gene
expression showed moderate fluctuations, with an initial significant downregulation at 4 and 12 h
(F6,27 = 9.28, 0.82-fold, ** p = 0.0042 and 0.91-fold, * p = 0.0243) followed by a return to baseline at 24 h
(1.02-fold, p = 0.8741) and again a modest reduction at 36 and 48 h (0.88-fold, ** p = 0.0049 and 0.93-fold,
* p = 0.0353) (Figure 5, panels B–F).
Figure 5. Cont.
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Figure 5. Time-course analyses of downregulated miRNAs following LPS exposure. (A) Heatmap
showing the overall pattern of expression of the dysregulated miRNAs over time. Each bar graph
depicts the expression profile of (B) rno-miR-181b; (C) rno-miR-145; (D) rno-miR-27a; (E) rno-miR-340
and (F) rno-miR-132 after treatment with 1 µg/mL LPS at different time points (0, 2, 4, 12, 24, 36 and
48 h). Ctrl = time 0. Data shown are the mean fold change ± SEM, obtained from two independent
experiments, each performed using separate biological replicates (n = 4). * p < 0.05, ** p < 0.01 or
*** p < 0.001 vs. Ctrl; repeated measures ANOVA followed by Fisher’s LSD test.
2.5.2. Upregulated miRNAs
Rno-miR-21 was upregulated at significant levels after 2 and 4 h LPS treatment (F6,27 = 23.76,
1.28-fold, ** p = 0.0016 and 1.32-fold, *** p = 0.0009). Expression peaked at 12 h (1.43-fold increase,
** p = 0.0025) but diminished at 24 and 36 h (1.16-fold, * p = 0.0364 and 1.23-fold, ** p = 0.0061) to finally
return to baseline levels at 48 h (1.06-fold, p = 0.2235). Expression of rno-miR-206 increased about
1.5-fold at 2 h (F6,27 = 37.66, ** p = 0.0017), lowered to about 1.2-fold at 4 and 12 h (** p = 0.0062 and
* p = 0.0184) and raised again at 24, 36 and 48 h (1.55-fold at 24 h *** p = 0.0002, 1.58-fold at 36 h
** p = 0.0014 and 1.43-fold at 48 h ** p = 0.0019). Rno-miR-146a increased significantly after 2, 4 h (F6,27
= 41.61, 1.32-fold, ** p = 0.0014 and 1.43-fold, ** p = 0.0044) and reached its peak of expression by 12 h
(1.65-fold, *** p = 0.0003), followed by a downwards slope at 24, 36 and 48 h (1.23-fold, * p = 0.012;
1.34-fold, ** p = 0.0007 and 1.1-fold, p = 0.1773). LPS induction of Rno-miR-34a was observed both
at 2 and 4 h post-LPS exposure (F6,27 = 62.62, 1.43-fold, *** p = 0.0006 and 1.54-fold, *** p = 0.0002,
respectively), decreased but was still significantly upregulated after 12 h (1.11-fold * p = 0.0418) to then
further increase at later time points (1.65-fold at 24 h, *** p = 0.0005; 1.58-fold at 36 h, ** p = 0.0014;
1.7-fold at 48 h, *** p = 0.0005). The expression profile of rno-miR-155 followed an inverted U-shape,
with transcripts significantly upregulated up to 24 h (F6,27 = 35.18, 1.05-fold at 2 h, p = 0.5803; 1.52-fold
at 4 h, ** p = 0.008; 1.87-fold at 12 h, ** p = 0.0027 and 1.9-fold at 24 h, ** p = 0.0084) to gradually
attenuate at 36 and 48 h (1.68-fold Vs. control, ** p = 0.0018 and 1.32-fold, * p = 0.026, respectively).
With regards to rno-miR-204, the overall increase was moderate but statistically significant, with a
peak induction of 1.32-fold observed both after 24 and 48 h exposure to LPS (F6,27 = 9.173, ** p = 0.0041
and 0.0088, respectively). A gradient increase in rno-miR-29a was observed in SCs exposed to LPS.
Transcripts were increased 1.45-fold at 2 h (F6,27 = 20.72, ** p = 0.0012), 1.63-fold at 4 h (** p = 0.0041),
1.82-fold at 12 h (** p = 0.0019), followed by a more blunted upregulation from 24 h onwards (1.64-fold
at 24 h, *** p = 0.001; 1.57-fold at 36 h, ** p = 0.0011 and 1.42-fold at 48 h, ** p = 0.0063) (Figure 6,
panels A–G).
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Figure 6. Time-course analyses of upregulated miRNAs following LPS exposure. Each bar graph
depicts the expression profile of (A) rno-miR-21; (B) rno-miR-206; (C) rno-miR-146a; (D) rno-miR-34a;
(E) rno-miR-155; (F) rno-miR-204 and (G) rno-miR-29a after treatment with 1 µg/mL LPS at different
time points (0, 2, 4, 12, 24, 36 and 48 h). Ctrl = time 0. Data shown are the mean fold change ± SEM,
obtained from two independent experiments, each performed using separate biological replicates
(n = 4). * p < 0.05, ** p < 0.01 or *** p < 0.001 vs. Ctrl; repeated measures ANOVA followed by Fisher’s
LSD test.
2.6. Correlations between Dysregulated miRNAs and VIP/PACAP System mRNAs in LPS Exposed RT4 SCs
In the effort to define if the pattern of changes of the dysregulated miRNAs correlated with the
changes occurred in the VIP/PACAP system in our cell model, we sought to conduct linear regression
analyses. Only significant correlations are shown (p < 0.05). We found three positive (Figure 7, panels
A–C) and four inverse correlations (Figure 7, panels D–G) with the VIP/PACAP family components.
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None of the investigated miRNAs correlated with Adcyap1 (PACAP gene) transcripts in SCs treated
with LPS the expression. On the other hand, rno-miR-155 showed a significant positive correlation with
Vip mRNAs (r2 = 0.764, p = 0.023) and so did rno-miR-145 with the PACAP-preferring receptor Adcyap1r1
mRNAs (r2 = 0.719, p = 0.033). Noteworthy, among the dysregulated miRNAs, 1 significant positive and
2 inverse correlations were found with Vipr1 transcripts: rno-miR-340 (r2 = 0.783, p = 0.019), rno-miR-155
(r2 = 0.944, p = 0.001) and rno-miR-29a (r2 = 0.705, p = 0.036). Finally, two inverse relationships were
computed for Vipr2 gene: with rno-miR-21 (r2 = 0.764, p = 0.023) and rno-miR-146a (r2 = 0.767, p = 0.022).
Figure 7. Scatterplots and regression lines showing the relationship between dysregulated miRNAs
and the expression profile of VIP/PACAP system components following exposure to LPS. Only
significant correlations are shown. Positive correlations were found between (A) rno-miR-155 and Vip;
(B) rno-miR-145-5p and Adcyap1r1 and (C) rno-miR-340-5p and Vipr1 mRNAs. Inverse relationships
were found between (D) rno-miR-155 and Vipr1; (E) rno-miR-29a and Vipr1; (F) rno-miR-21 and Vipr2
and (G) rno-miR-146a and Vipr2. Coefficients of determination (r2) and related p values are shown in
each panel.
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3. Discussion
In this study, we have unveiled a subset of miRNAs whose expression levels are dysregulated in
RT4 SCs in vitro when exposed to an immune challenge with LPS. We performed these investigations
in the attempt to gain mechanistic insights that could aid in modelling the cell behavior of SCs in vivo
when exposed to the local inflammatory microenvironment found following nerve injury. The panel
of miRNAs we analyzed was selected on the basis of prior evidence documenting their specific
involvement in regulating certain biological functions relevant to repair SCs (please refer to Table 2
above for details), a de-differentiated phenotype that SCs acquire to aid in the nerve regeneration
process following damage. In addition, we conducted regression analyses and identified significant
correlations among some of the perturbed miRNAs profiles and the expression pattern of components
of the neuroprotective VIP/PACAP system. To the best of our knowledge, this is the first study to:
(1) detect specific changes in the expression pattern of VIP/PACAP system following LPS exposure in
rat RT4 SCs and (2) identify a subset of dysregulated miRNAs in RT4 SCs whose expression pattern
correlates with changes to the VIP/PACAP system.
The current investigations were conceived based on previous findings demonstrating that the
VIP/PACAP system is involved in regulating multiple biological actions in RT4 SCs. Some of these
functions included promoting the shift to a proliferative state through the inhibition of programmed
cell death [6] or the induction of gene expression and activity of a class of proteolytic enzymes
involved in the clearance of cell debris along the nerve sheath conduit [5], a condition necessary
for axonal regeneration. We reasoned that such a variety of biological functions in SCs could not
be simply the result of the ligand-receptor operated activation of transduction systems, but likely
involved a more subtle and complex machinery able to fine-tune and coordinate the expression of
a whole set of genes. MiRNAs, which appeared on the scene just less than two decades ago [12],
are tiny non-coding RNAs that control several pathways through the suppression of hundreds of
genes and, in turn, are reciprocally controlled by various regulatory networks [39]. As evidence
suggests, these post-transcriptional repressors of gene expression appeared the most suitable targets to
investigate in our cell model.
Initially, our approach was to establish the suitability of our cell system as an effective in vitro
model that could at least in part mimic the biological response of SCs to an “immune challenge”. Hence,
we performed a series of experiments aimed at assessing which was the optimal concentration of LPS
to use as well as the correct time window of exposure (Figure 1). Secondly, we assessed whether LPS
triggered the release of pro-inflammatory cytokines/chemokines by RT4 SCs (Figure 2). Surprisingly,
we found that RT4 SCs are resilient to the detrimental effects of LPS, and signs of apoptosis were
apparent only at reasonably high concentrations (above 10 µg/mL) after 24 h. We could not ascertain
the exact mechanisms for such increased cell resistance, but based on prior observations we assumed
that the endogenous upregulation of the protective peptides VIP and PACAP might have had a
role (Figures 3 and 4), with a similar process to that observed in primary SCs exposed to oxidative
insult [40]. Regarding the inflammatory response, LPS-stimulated RT4 SCs secreted higher levels
of several pro-inflammatory cytokines/chemokines, albeit each reaching their individual peak of
secretion at different times. Noteworthy, of all the tested cytokines/chemokines, which peaked at
around 12–24 h post-LPS, IL-18 reached its peak as early as after 4 h. This finding is in agreement with
studies supporting the important role of this cytokine in priming neutrophil recruitment at the earliest
stages of inflammation [41] to promote adaptive immune cell recruitment thereafter [42]. Moreover,
the overall increase in cytokine levels is consistent with the idea of an active involvement of SCs in
promoting the recruitment of macrophages and resident glia at the injury site [17,43].
3.1. Dysregulated Expression of the VIP/PACAP System upon LPS Exposure
Both VIP and PACAP are two well-established naturally occurring peptides endowed with neuro-
and glioprotective properties [44]. Due to their protective function, endogenous levels of VIP and
PACAP are usually upregulated in response to changes in microenvironment that would otherwise
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damage or kill cells, most likely as a self-preservation mechanism. However, the peptides are also
pivotal in a variety of other important biological functions, some of which seem to be cell/tissue type
specific [45–47]. In cultured RT4 SCs, both peptides inhibit apoptosis [6], trigger fibrinolytic activity [5],
stimulate the production of other trophic molecules [40] and ultimately promote myelinogenesis [4].
Here we found that upon LPS stimulation, VIP and PACAP transcripts and proteins were significantly
increased, whilst unexpectedly, the expression of VPAC1 and VPAC2 receptors was diminished. Based
on findings reporting that the actions of VIP/PACAP are through autocrine/paracrine signaling
loops [48,49], we reasoned that the inverse relationship between peptides and receptors could reflect a
regulatory mechanism where inflammation triggers receptors internalization and arrests the release
of peptides. This would occur in the effort to promote the intracellular accumulation of both VIP
and PACAP at the benefit of other cellular functions, whilst preserving bioenergy consumption.
Alternatively, it is possible that the inversely regulated expression of VIP/PACAP peptides and VPAC
receptor subtypes is needed to dampen some of the functions normally elicited in SCs, such as the
pro-myelinating properties of the peptides, where both peptides and receptors need to be upregulated
to induce the expression of myelin-markers [4]. However, further investigations are warranted to
verify these hypotheses.
3.2. Dysregulated miRNAs and Their Potential Relationship with the VIP/PACAP System
SCs surrounding damaged axons have the ability to undergo a de-differentiation program that
is driven by a transcriptional program that is critical for nerve regeneration. In part, this program is
thought to be initiated during the earliest phase of nerve injury, when overt signs of inflammation are
observed at the injury site. Evidence suggests that miRNAs might play a central role in controlling
cellular reprogramming of SCs [50]. According to an emerging theory, the multifaceted process of
de-differentiation in SCs is controlled by the interplay of cell-intrinsic programs and cell-extrinsic
signals. Immediately after injury, degenerating axons release signaling molecules to trigger SC
de-differentiation, presumably through the activation of cell-intrinsic transcriptional programs
coordinated by miRNAs. Some of these programs are known to be partaken by transcription factors
such as c-jun [51], DNA cofactors such as the proliferating cell nuclear antigen (PCNA) [52] and
different dedifferentiating receptors, including platelet-derived growth factor (PDGF) B [53]. Extrinsic
pro-inflammatory signals from the microenvironment would then superimpose on these programs to
adapt SC function to the specific repair requirements of the surrounding tissue [10]. In line with this
theory, this study revealed that at least 5 of the selected miRNAs were significantly downregulated
and 7 were upregulated using our experimental model.
As previously validated by other research groups (please refer to Table 2 for details) the functions
of the dysregulated miRNAs ranged from the control of cell proliferation (miR-27a), cell migration
(miR-132 and miR-29a), myelinogenesis (miR-29a), apoptosis (miR-204), response to inflammation
(miR-155) and clearance of debris (miR-340), to the control of de-differentiation genes (miR-34a, miR-145
and miR-181b), all collectively involved in the phenotypic regression of SCs to a proliferative state.
Interestingly, some of the miRNAs were affected by LPS treatment in a manner consistent with that
previously reported to attain the expected biological shifts. For instance, miR-340, which directly
targets the 3′ untranslated region (UTR) of the proteolytic enzyme tissue plasminogen activator
gene (tPA) [38], was significantly downregulated in RT4 SCs exposed to LPS; suggesting that upon
inflammatory stimuli SCs may increase their proteolytic activity to promote debris clearance and
extracellular matrix remodeling by de-repressing tPA gene expression. Another downregulated miRNA
in this study, i.e., miR-181b, has been previously shown to repress the release of pro-inflammatory
cytokines in astrocytes [32]. Despite the difference in cell type, it is likely that the attenuation of
miR-181 may exert a comparable function in SCs to boost cytokine release.
Of the 7 aberrantly upregulated miRNAs, 2 were more predominantly increased, i.e., miR-155 and
miR-29a (Figure 6, panels E, G). MiR-155 increase has been implicated in the pathogenesis of various
inflammatory disorders [31], including the triggering of autoimmune inflammation by T cells [54]
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and potentiation of LPS-induced release of pro-inflammatory cytokines by monocytes in cells exposed
to hypothermia [55]. In addition, this miRNA seems to be regulated following activation of toll-like
receptors [31], a family of pattern recognition receptors that also recognize and are activated by LPS.
Collectively, these findings may imply that the increased miR-155 might be partly responsible for the
release of pro-inflammatory mediators in LPS-exposed RT4 SCs. The other highly upregulated miRNA,
miR-29a, is involved in the suppression of peripheral myelin protein 22 (PMP22) gene in SCs [20].
PMP22 is an essential component of the myelin sheath and is required for myelinogenesis. MiR-29a
driven gene repression of PMP22 could halt SC pro-myelinating function during inflammation, thereby
promoting the transition to a non-myelinating phenotype.
Taken together, the observed patterns of dysregulations in the investigated miRNAs may
explain, at least in part, some of the biological changes SCs might undergo following exposure
to an inflammatory trigger. Due to the number of gene targets regulated by these non-coding RNAs,
it is of no surprise that the coordinated activity of a few miRNAs could potentially generate important
changes in cell functioning and biology. With this in mind, we decided to take a step further and
analyze our data in the attempt to find, if any, a correlation with the temporal gene expression profile
of genes pertaining to the VIP/PACAP system. Unfortunately, we could not find any significant
relationship between our miRNAs and one of the dysregulated genes, the PACAP gene. However,
we identified 3 positive correlations; one between miR-155 and Vip transcripts, the second between
miR-145 and PAC1 receptor gene (Adcyap1r1) and the third one between miR-340 and VPAC1 gene
(Vipr1) (Figure 7, panels A–C). These relationships were found to be quiet unusual in view of the
suppressive nature of miRNAs on transcripts, which usually results in inverse correlations. However,
it is not always the case. As elegantly described by Dugas and Notterpek [56], some miRNAs may
function as “guardians of the transcriptome” by preventing inappropriately expressed mRNAs from
being translated into functional proteins that could otherwise affect the health of the cell. In our setting,
it is possible that uncontrolled induction of VIP, PAC1 and VPAC1 receptor genes by LPS would have
impeded the appropriate cell response to inflammation. MiR-155, -145 and -340, by targeting these
“inappropriate genes” may have prevented or limited excessive translation. Although not confirmed
by direct gene targeting testing, this perspective appears fascinating. On the other hand, two couples of
miRNAs per gene (i.e., miR-155/-29a vs. Vipr1 and miR-21/-146a vs. Vipr2 genes, respectively) exhibited
the canonical inverse relationships with their putative targets, hence providing a plausible explanation
for the robust reduction of protein levels we reported.
In conclusion, the present study demonstrated that an inflammatory insult, mimicked by LPS,
causes significant dysregulations of two biologically relevant and potentially interrelated systems in
SCs. However, it should be noted that the significance of these findings in the broader context of nerve
injury should be taken with care in view of the fact that the studies have been carried out in RT4 SCs
and not in primary cell lines. With this in mind, further studies are required to investigate whether
primary cultures of SCs isolated from injured peripheral nerves would exhibit a similar pattern of
dysregulations as that observed in this study. In addition, the involvement of the VIP/PACAP system
in the reprogramming of SCs still needs to be comprehensively explored. Additional studies aimed at
investigating for potential correlations between the identified miRNAs and better validated targets
such as c-jun, PCNA, PDGF receptors are warranted in the future. Nonetheless, these findings may
aid in the identification of post-transcriptional mechanisms whose dysregulations could be critical in
enabling or determining SCs shift from myelinating to “repair cells” following damage, which could
become targets for intervention to aid in promoting peripheral nerve recovery following trauma.
4. Materials and Methods
4.1. RT4 Schwann Cell Line
The present study was performed using the rat Schwann cell line RT4-D6P2T (ATCC number
CRL-2768) obtained from the American Type Culture Collection (Rockville, MD, USA). Cells
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were cultured in Dulbecco’s modified Eagle’s medium (DMEM) and supplemented with 10% of
heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (Lonza,
Milan, Italy). Cells were incubated at 37 ◦C in a humidified atmosphere with 5% CO2. Cells were
grown to reach about 80–85% confluence in media containing 10% fetal bovine serum (FBS) before
treatment with lipopolysaccharides (LPS) from Escherichia coli O111:B4 (cat no# L4391, Sigma Aldrich,
St. Louis, MO, USA) at the concentrations and time regimens described in the related subsections. LPS
was diluted in water from the stock solution and stored at −80 ◦C until needed.
4.2. Cell Viability Assay (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay)
To assess cell viability, we used the cell proliferation kit I (MTT, Roche Applied Science,
Monza, Italy) according to previously reported protocols [57]. RT4 cells were treated with a
range of concentrations (0, 0.1, 1, 10 and 100 µg/mL) of LPS (Sigma Aldrich) for 24 h or at
the fixed concentration of 1µg/mL for time-course studies. Briefly, cells were seeded into flat
bottom 96-well plates at a concentration of 1 × 105 cells/well. DMEM containing 0.5 mg/mL
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich) was added in
each well. Following incubation for 2 h at 37 ◦C, medium was removed, and 100 µL of dimethyl
sulphoxide (DMSO) was added. Formazan obtained by the cleavage of the yellow tetrazolium salt MTT
was measured using a spectrophotometer by absorbance change at 550–600 nm using a microplate
reader (BioRad, Milan, Italy).
4.3. Hoechst 33258 Nuclear Staining
To appraise the typical morphological features of apoptotic degeneration by fluorescence
microscopy we stained RT4 cells with the nuclear dye Hoechst 33258 as previously described [40].
Cells were fixed with a solution containing methanol/acetic acid (3:1 v/v) for 30 min, then washed
three times in PBS and incubated for 15 min at 37 ◦C with 0.4 µg/mL Hoechst 33258 dye
(Bis-benzimide). After being rinsed in milliQ water, cells were visualized for determination of
nuclear chromatin morphology using the Axiovert 40 fluorescence microscope (Carl Zeiss Inc., Jena,
Germany). Apoptotic/dead cells were recognized on the basis of nuclear shrinkage and/or chromatin
fragmentation. Each condition was replicated three times in each experiment. Apoptotic and normal
cells were recognised by analyzing three different fields per dish following a fixed pattern.
4.4. Multiplex Cytokine Assays
Pre-blended customized multiplex cytokine assays (Bio-Plex Pro Rat Cytokine I 6plx XPL, Bio-Rad
Laboratories, Milan, Italy) were used, according to the manufacturer’s instructions, to determine the
concentration of IL-1β, IL-6, IL-18, IL-17A, MCP-1 and TNFα in conditioned media from control and
LPS-treated Schwann cells at different time points (0, 2, 4, 12, 24, 36 and 48 h). Samples were mixed
1:2 in diluent and stored at 4 ◦C until used. To start the assay, 50 µL of vortexed magnetic microbeads
were added to each well. Beads were then washed twice with Bio-Plex Pro wash buffer using a
magnetic plate washer (Tecan HydroFlex, Crailsheim, Germany). 50 µL of standards and samples were
added to the wells. Plates were kept in the dark before being incubated at room temperature for 1 h on
a plate mixer. Plates were washed thrice and 25 µL of detection antibodies were added and allowed
to incubate for 30 min. Plates were washed 3 further times and 60 µL of streptavidin-phycoerythrin
reporter (SA-PE) was added to each well, followed by 10 min incubation. Next, plates were washed
three times before adding 125 µL assay buffer to each well. Plates were then sealed and stored at
4 ◦C until acquisition. Data were collected using a Bio-Plex 100 suspension array system (Bio-Rad
Laboratories, Milan, Italy). Plates were shaked at 1000 rpm for 30 s prior to reading. Standard curves
were optimised and sample cytokine concentrations determined using Bio-Plex Manager software
(Bio-Rad Laboratories).
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4.5. RNA Isolation, cDNA Synthesis and Gene Expression Analyses by Quantitative Real-Time PCR
Total RNAs from RT4-D6P2T cells exposed to different treatments were isolated using 1 mL TRIzol
reagent (Invitrogen, Monza, Italy) and 0.2 mL chloroform and precipitated with 0.5 mL isopropanol.
Pellets were washed with 75% ethanol and air dried. MiRNAs were extracted from cells pellets using
the Qiagen miRNeasy mini kit (Qiagen, Hilden, Germany) and finally eluted in 40 µL of elution buffer,
according to manufacturer’s instructions. Single stranded cDNAs were synthesized by incubating total
RNA (2 µg) with SuperScript III RNase H-reverse transcriptase (200 U/µL) (Invitrogen); Oligo-(dT)20
primer (100 nM) (Invitrogen); 1 mM dNTP mix (Invitrogen), dithiothreitol (DTT, 0.1 M), recombinant
RNase-inhibitor (40 U/µL) at 42 ◦C for 1 h in a final volume of 20 µL. Reaction was terminated by
incubation of samples at 70 ◦C for 10 min.Aliquots of cDNA (100 ng) from each sample and external
standards (purified amplicons, ranging from 102 to 108 copies) were amplified in parallel reactions,
according to previously detailed protocols [58]. Briefly, primer pairs were designed and optimised to
specifically target Vip, adcyap1, adcyap1r1, Vipr1, Vipr2 the S18 ribosomal subunit (reference gene) coding
regions mRNAs, using the sequences detailed in Table 1. Each PCR reaction contained 0.5 µM primers,
1.6 mM MgCl2+, 1× (Roche Diagnostic, Monza, Italy). Amplifications were performed using the Light
Cycler 480 instrument (Roche Diagnostic) using the following program setting: (1) cDNA denaturation
(1 cycle: 95 ◦C for 2 min); (2) quantification (45 cycles: 95 ◦C for 10 s, 60 ◦C for 30 s, 72 ◦C for 7 s);
(3) melting curve analysis (1 cycle: 95 ◦C for 0 s, 65 ◦C for 15 s, 95 ◦C for 0 s); (4) cooling (1 cycle: 40 ◦C
for 30 s). PCR products specificity was evaluated by melting curve analysis. Changes in expression
levels were computed as mean fold changes, calculated using the comparative Ct method [59]. ∆Ct
was obtained by subtracting the mean Ct of each sample to the mean Ct of the reference gene under
the exact experimental conditions. For the quantification of each gene we considered cDNAs from
untreated RT4-D6P2T cells as the calibrator sample. The ∆∆Ct of each sample was then calculated
by subtracting calibrator ∆Ct to treated sample ∆Ct. The formula 2−∆∆Ct was used to calculate fold
changes. Baseline fold change for each calibrator sample were set to 1.
4.6. SDS-Polyacrylamide Gel Electrophoresis and Western Blotting
Western blot analysis was performed in lysates from RT4 cells following exposure to 1 µg/mL
LPS for 24 h. Briefly, proteins were extracted using an ice-cold lysis buffer containing 20 mM Tris
(pH 7.4), 2 mM EDTA, 0.5 mM EGTA; 50 mM mercaptoethanol, 0.32 mM sucrose, a protease inhibitor
cocktail and the phosphatase inhibitor PhosSTOP (Roche Applied Science, Monza, Italy) using a
Teflon-glass homogenizer and then sonicated twice for 20 s using an ultrasonic probe, followed
by centrifugation at 10.000 g for 10 min at 4 ◦C. Protein concentrations were determined using the
Quant-iT Protein Assay Kit (Invitrogen, Carlsbad, CA, USA). Sample proteins (30 µg) were diluted
in 4× Laemmli buffer (Invitrogen), heated at 70 ◦C for 10 min and then separated on a BioRad
Criterion XT 4–20% Tris-glycine gel (BioRad Laboratories) by electrophoresis and then transferred
to PVDF membrane (Invitrogen). Non-specific sites were blocked with the Odyssey Blocking Buffer
(Li-Cor Biosciences, Lincoln, NE, USA). Transfer was examined using a protein molecular weight
marker (BioRad Laboratories). Western blot analyses were performed using the following primary
rabbit polyclonal antibodies: PAC1 receptor (1:500, cat no# sc-30018, Santa Cruz Biotechnology Inc.,
Heidelberg, Germany), VPAC1 receptor (1:800, cat no# sc-30019, Santa Cruz Biotechnology Inc.),
VPAC2 receptor (1:400, cat no# sc-30020, Santa Cruz Biotechnology Inc.), PACAP peptide (1:500, cat
no# sc-25439, Santa Cruz Biotechnology Inc.), VIP peptide (1:1000, cat no# GTX129461, GeneTex) and
GAPDH (1:2000, cat no# sc-47724, Santa Cruz Biotechnology Inc.). The secondary goat anti-rabbit
antibody used was the IRDye 800CW, (cat #926-32211; Li-Cor Biosciences), which was used at the
dilution of 1:20000. Blots were scanned using an Odyssey Infrared Imaging System (Li-Cor Biosciences)
as detailed in previous work [60]. Densitometry was performed using the ImageJ software (NIH,
Bethesda, MD; available at http://rsb.info.nih.gov/ij/). Optical densities of target proteins were
normalized to GAPDH, which served as loading control. Background correction was also applied to
reduce variability across membranes.
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4.7. MiRNA Profiling
MiRNA concentrations and purity were determined by NanoDrop (ThermoFisher Scientific,
Waltham, MA, USA). Only where miRNA extractions yielded ≥600 ng samples were used for
downstream cDNA synthesis, which was obtained using the miScript II RT Kit (Qiagen). MiRNA
profiling was then performed on cDNA templates using customised Rat miScript miRNA PCR arrays
(384 well format from Qiagen) in a Roche LightCycler 480 instrument (Roche Diagnostics). Each cDNA
was pre-mixed with the miScript Universal primer, QuantiTect SYBR Green PCR Master Mix and
RNase-free water to a final volume of 10 µL before being added to the plates containing miRNA
forward primers. The qPCR assay was set up as follows: 95 ◦C for 15 min; 40 cycles of 94 ◦C for 15 s;
55 ◦C for 30 s; and 70 ◦C for 30 s. The relative expression was calculated using the ∆∆Ct method
as indicated above. Values were normalized to levels of the non-coding small nuclear RNA U6
(U6 snRNA).
4.8. Statistical Analyses
Statistical analysis was performed using GraphPad Prism® version 7.02 software (GraphPad
Software, Inc., La Jolla, CA, USA). Data were tested for normality with the Kolmogorov–Smirnov
test. All variables were normally distributed. Unpaired Student’s t test was used for comparisons
between two groups, whereas Dunnett’s post-hoc tests (unless otherwise indicated) were used to
analyze whether groups’ data were significantly different following analysis of variance (between three
or more treatment groups). The gene expression data collected from LPS treated samples at different
time points were also analysed using linear regression to test for significant correlations between
VIP/PACAP mRNA and select miRNA expression levels over time. Only where statistically significant
correlations occurred are the data shown (Figure 7). All other correlations were not statistically
significant. P-values of less than 0.05 (p < 0.05) were considered significant. All data are presented as
the mean ± SEM and are the result of at least three independent determinations.
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